An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.
about
Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasoundOncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cellsRapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hostspH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesisAdenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumorsComplement activation and cell uptake responses toward polymer-functionalized protein nanocapsules.Advances and future challenges in adenoviral vector pharmacology and targeting.Virotherapy of neuroendocrine tumors.AdCD40L--crossing the valley of death?Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Mutation of herpesvirus Saimiri ORF51 glycoprotein specifically targets infectivity to hepatocellular carcinoma cell lines.Human coagulation factor X-adenovirus type 5 complexes poorly stimulate an innate immune response in human mononuclear phagocytes.In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors.Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies
P2860
Q30446996-AE3D8E6C-C391-469D-AD85-0282FEB6B49CQ34178183-4CBD6E0D-7649-413A-800A-8E9C1F0DCD19Q34473365-A0304BDD-A55F-4838-B26F-515BC1C0CC69Q34984515-0A974BAC-339F-49C1-BF78-B29DA52A6406Q35569909-288D6CA4-1A58-4FBD-B78A-CB8F3CC8639EQ35599319-36C303B8-65DD-4F84-B95A-0D614ED3BCF6Q35878143-D041479E-0C9C-49FA-BD92-2B26E1EE509AQ37859842-C173E510-3651-4EF5-BC6B-2E97DDD0EB9CQ37989391-8D6F255D-CB96-4F2F-82F0-593008AECAF3Q38026926-F9A3C030-1A87-48BF-8362-A1E41E7A4D24Q38073096-0534C6D9-4D63-4D03-BE81-CE74DFF86AE0Q38808823-ADFADEF4-31D5-4B3E-A5E4-BB84D5AE6ECEQ39613108-318C1B9C-65E0-40EA-9F81-1D58A6829312Q41650213-6FD4BED3-38B8-46F5-B59D-E6687F2B4B27Q45866594-ACD64B63-4B85-4BE5-BAE4-9F6A3932FEDFQ55365677-319263FB-D8E9-4B92-933A-F50A4E8D9D84Q57469731-AAB8A71B-0DC1-437D-8CD5-478EAD1AB278
P2860
An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
An ex vivo loop system models ...... rotype 5 in whole human blood.
@en
An ex vivo loop system models ...... rotype 5 in whole human blood.
@nl
type
label
An ex vivo loop system models ...... rotype 5 in whole human blood.
@en
An ex vivo loop system models ...... rotype 5 in whole human blood.
@nl
prefLabel
An ex vivo loop system models ...... rotype 5 in whole human blood.
@en
An ex vivo loop system models ...... rotype 5 in whole human blood.
@nl
P2093
P2860
P356
P1433
P1476
An ex vivo loop system models ...... rotype 5 in whole human blood.
@en
P2093
A Danielsson
B M Nilsson
S Kochanek
T H Tötterman
P2860
P2888
P304
P356
10.1038/GT.2010.18
P577
2010-03-11T00:00:00Z
P5875
P6179
1015791478